Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or
selective serotonin reuptake inhibitors. Br J
2001; 178: 234–41.
Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, et al. Evaluation of outcomes with citalopram for
depression using measurement-based care in STAR*D:
implications for clinical practice. Am J
Franchini, L, Serretti, A, Gasperini, M, Smeraldi, E. Familial concordance of fluvoxamine response as a
tool for differentiating mood disorder pedigrees.
J Psychiatr Res
1998; 32: 255–9.
Uher, R, McGuffin, P. The moderation by the serotonin transporter gene of
environmental adversity in the aetiology of mental illness: review and
methodological analysis. Mol Psychiatry
2008; 13: 131–46.
Lesch, KP, Balling, U, Gross, J, Strauss, K, Wolozin, BL, Murphy, DL, et al. Organization of the human serotonin
transporter gene. J Neural Transm Gen
1994; 95: 157–62.
Smeraldi, E, Zanardi, R, Benedetti, F, Di, BD, Perez, J, Catalano, M. Polymorphism within the promoter of the serotonin
transporter gene and antidepressant efficacy of
fluvoxamine. Mol Psychiatry
1998; 3: 508–11.
Serretti, A, Kato, M, De, RD, Kinoshita, T. Meta-analysis of serotonin transporter gene promoter
polymorphism (5-HTTLPR) association with selective serotonin reuptake
inhibitor efficacy in depressed patients. Mol
2007; 12: 247–57.
Kim, H, Lim, SW, Kim, S, Kim, JW, Chang, YH, Carroll, BJ, et al. Monoamine transporter gene polymorphisms and
antidepressant response in Koreans with late-life
2006; 296: 1609–18.
Kraft, JB, Peters, EJ, Slager, SL, Jenkins, GD, Reinalda, MS, McGrath, PJ, et al. Analysis of association between the serotonin
transporter and antidepressant response in a large clinical
sample. Biol Psychiatry
2007; 61: 734–42.
Mrazek, DA, Rush, AJ, Biernacka, JM, O'Kane, DJ, Cunningham, JM, Wieben, ED, et al. SLC6A4 variation and citalopram
response. Am J Med Genet B Neuropsychiatr
2009; 150B: 341–51.
Gelernter, J, Cubells, JF, Kidd, JR, Pakstis, AJ, Kidd, KK. Population studies of polymorphisms of the serotonin
transporter protein gene. Am J Med Genet
1999; 88: 61–6.
Hu, X, Oroszi, G, Chun, J, Smith, TL, Goldman, D, Schuckit, MA. An expanded evaluation of the relationship of four
alleles to the level of response to alcohol and the alcoholism
risk. Alcohol Clin Exp Res
Kraft, JB, Slager, SL, McGrath, PJ, Hamilton, SP. Sequence analysis of the serotonin transporter and
associations with antidepressant response. Biol
2005; 58: 374–81.
Wendland, JR, Martin, BJ, Kruse, MR, Lesch, KP, Murphy, DL. Simultaneous genotyping of four functional loci of
human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531.
2006; 11: 224–6.
Braganca, J, Eloranta, JJ, Bamforth, SD, Ibbitt, JC, Hurst, HC, Bhattacharya, S. Physical and functional interactions among AP-2
transcription factors, p300/CREB-binding protein, and
CITED2. J Biol Chem
2003; 278: 16021–9.
Damberg, M. Transcription factor AP-2 and monoaminergic
functions in the central nervous system. J Neural
2005; 112: 1281–96.
Hu, XZ, Lipsky, RH, Zhu, G, Akhtar, LA, Taubman, J, Greenberg, BD, et al. Serotonin transporter promoter
gain-of-function genotypes are linked to obsessive-compulsive
disorder. Am J Hum Genet
2006; 78: 815–26.
Martin, J, Cleak, J, Willis-Owen, SA, Flint, J, Shifman, S. Mapping regulatory variants for the serotonin
transporter gene based on allelic expression imbalance.
2007; 12: 421–2.
MacKenzie, A, Quinn, J. A serotonin transporter gene intron 2 polymorphic
region, correlated with affective disorders, has allele-dependent
differential enhancer-like properties in the mouse
embryo. Proc Natl Acad Sci USA
1999; 96: 15251–5.
Joyce, PR, Mulder, RT, Luty, SE, McKenzie, JM, Miller, AL, Rogers, GR, et al. Age-dependent antidepressant
pharmacogenomics: polymorphisms of the serotonin transporter and G
protein beta3 subunit as predictors of response to fluoxetine and
nortriptyline. Int J
2003; 6: 339–46.
Tauscher, J, Verhoeff, NP, Christensen, BK, Hussey, D, Meyer, JH, Kecojevic, A, et al. Serotonin 5-HT1A receptor binding potential
declines with age as measured by [11C]WAY-100635 and PET.
2001; 24: 522–30.
van Dyck, CH, Malison, RT, Seibyl, JP, Laruelle, M, Klumpp, H, Zoghbi, SS, et al. Age-related decline in central serotonin
transporter availability with [(123)I]beta-CIT SPECT.
Yamamoto, M, Suhara, T, Okubo, Y, Ichimiya, T, Sudo, Y, Inoue, M, et al. Age-related decline of serotonin transporters
in living human brain of healthy males. Life
2002; 71: 751–7.
Hiroi, R, McDevitt, RA, Neumaier, JF. Estrogen selectively increases tryptophan
hydroxylase-2 mRNA expression in distinct subregions of rat midbrain
raphe nucleus: association between gene expression and anxiety behavior
in the open field. Biol Psychiatry
2006; 60: 288–95.
Biegon, A, McEwen, BS. Modulation by estradiol of serotonin receptors in
brain. J Neurosci
Sumner, BE, Fink, G. The density of 5-hydoxytryptamine2A receptors in
forebrain is increased at pro-oestrus in intact female
rats. Neurosci Lett
Wissink, S, van der, BB, Katzenellenbogen, BS, van der Saag, PT. Synergistic activation of the serotonin-1A receptor
by nuclear factor-kappa B and estrogen. Mol
2001; 15: 543–52.
Lu, NZ, Eshleman, AJ, Janowsky, A, Bethea, CL. Ovarian steroid regulation of serotonin reuptake
transporter (SERT) binding, distribution, and function in female
macaques. Mol Psychiatry
2003; 8: 353–60.
McQueen, JK, Wilson, H, Fink, G. Estradiol-17 beta increases serotonin transporter
(SERT) mRNA levels and the density of SERT-binding sites in female rat
brain. Brain Res Mol Brain Res
Walderhaug, E, Magnusson, A, Neumeister, A, Lappalainen, J, Lunde, H, Refsum, H, et al. Interactive effects of sex and 5-HTTLPR on
mood and impulsivity during tryptophan depletion in healthy
people. Biol Psychiatry
2007; 62: 593–99.
Sjoberg, RL, Nilsson, KW, Nordquist, N, Ohrvik, J, Leppert, J, Lindstrom, L, et al. Development of depression: sex and the
interaction between environment and a promoter polymorphism of the
serotonin transporter gene. Int J
2006; 9: 443–9.
Uher, R, Maier, W, Hauser, J, Marušič, A, Schmael, C, Mors, O, et al. Differential efficacy of escitalopram and
nortriptyline on dimensional measures of depression.
Br J Psychiatry
2009; 194: 252–9.
World Health Organization. The ICD–10
Classification of Mental and Behavioural Disorders: Clinical Descriptions
and Diagnostic Guidelines. WHO,
American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorder (4th
Wing, JK, Sartorius, N, Ustin, TB. Diagnosis and Clinical Measurement in Psychiatry. A
Reference Manual for SCAN. World Health
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to
change. Br J Psychiatry
1979; 134: 382–9.
Hamilton, M. A rating scale for depression.
J Neurol Neurosurg Psychiatry
Hamilton, M. Development of a rating scale for primary depressive
illness. Br J Clin Psychol
1967; 6: 278–96.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring
depression. Arch Gen Psychiatry
1961; 4: 561–71.
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new
comprehensive rating scale for psychotropic drugs and a cross-sectional
study of side effects in neuroleptic-treated patients.
Acta Psychiatr Scand Suppl
Uher, R, Farmer, A, Henigsberg, N, Rietschel, M, Mors, O, Maier, W, et al. Adverse reactions to
antidepressants. Br J Psychiatry
Uher, R, Farmer, A, Maier, W, Rietschel, M, Hauser, J, Marusic, A, et al. Measuring depression: comparison and
integration of three scales in the GENDEP study.
Freeman, B, Smith, N, Curtis, C, Huckett, L, Mill, J, Craig, IW. DNA from buccal swabs recruited by mail: evaluation
of storage effects on long-term stability and suitability for multiplex
polymerase chain reaction genotyping. Behav
De Bakker, PI, Yelensky, R, Pe'er, I, Gabriel, SB, Daly, MJ, Altshuler, D. Efficiency and power in genetic association
studies. Nat Genet
2005; 37: 1217–23.
Seldin, MF, Shigeta, R, Villoslada, P, Selmi, C, Tuomilehto, J, Silva, G, et al. European population substructure: clustering
of northern and southern populations. PLoS
2006; 2: e143.
Barrett, JC, Fry, B, Maller, J, Daly, MJ. Haploview: analysis and visualization of LD and
haplotype maps. Bioinformatics
2005; 21: 263–5.
Wittke-Thompson, JK, Pluzhnikov, A, Cox, NJ. Rational inferences about departures from
Hardy-Weinberg equilibrium. Am J Hum
2005; 76: 967–86.
Stephens, M, Donnelly, P. A comparison of Bayesian methods for haplotype
reconstruction from population genotype data. Am
J Hum Genet
2003; 73: 1162–9.
Stephens, M, Smith, NJ, Donnelly, P. A new statistical method for haplotype
reconstruction from population data. Am J Hum
2001; 68: 978–89.
Cordell, HJ. Estimation and testing of genotype and haplotype
effects in case-control studies: comparison of weighted regression and
multiple imputation procedures. Genet
2006; 30: 259–75.
Falush, D, Stephens, M, Pritchard, JK. Inference of population structure using multilocus
genotype data: linked loci and correlated allele
2003; 164: 1567–87.
Devlin, B, Roeder, K. Genomic control for association
Purcell, S, Neale, B, Todd-Brown, K, Thomas, L, Ferreira, MA, Bender, D, et al. PLINK: a tool set for whole-genome
association and population-based linkage analyses.
Am J Hum Genet
2007; 81: 559–75.
Zanardi, R, Serretti, A, Rossini, D, Franchini, L, Cusin, C, Lattuada, E, et al. Factors affecting fluvoxamine antidepressant
activity: influence of pindolol and 5-HTTLPR in delusional and
nondelusional depression. Biol
2001; 50: 323–30.
Weiss, LA, Abney, M, Cook, EH Jr, Ober, C. Sex-specific genetic architecture of whole blood
serotonin levels. Am J Hum Genet
Morgan, ML, Cook, IA, Rapkin, AJ, Leuchter, AF. Estrogen augmentation of antidepressants in
perimenopausal depression: a pilot study. J Clin
2005; 66: 774–80.
Soares, CN, Almeida, OP, Joffe, H, Cohen, LS. Efficacy of estradiol for the treatment of
depressive disorders in perimenopausal women: a double-blind, randomized,
placebo-controlled trial. Arch Gen
2001; 58: 529–34.
Katz, MM, Koslow, SH, Frazer, A. Onset of antidepressant activity: reexamining the
structure of depression and multiple actions of drugs.
1996; 4: 257–67.
Serretti, A, Mandelli, L, Lorenzi, C, Pirovano, A, Olgiati, P, Colombo, C, et al. Serotonin transporter gene influences the
time course of improvement of “core” depressive and somatic anxiety
symptoms during treatment with SSRIs for recurrent mood
disorders. Psychiatry Res
2007; 149: 185–93.
Hu, XZ, Rush, AJ, Charney, D, Wilson, AF, Sorant, AJ, Papanicolaou, GJ, et al. Association between a functional serotonin
transporter promoter polymorphism and citalopram treatment in adult
outpatients with major depression. Arch Gen
2007; 64: 783–92.
Murphy, GM Jr, Hollander, SB, Rodrigues, HE, Kremer, C, Schatzberg, AF. Effects of the serotonin transporter gene promoter
polymorphism on mirtazapine and paroxetine efficacy and adverse events in
geriatric major depression. Arch Gen
2004; 61: 1163–9.